Not buying any more, stuck in it for a while. Like the product / concept but POOR execution by Management.
No point in writing off, will see if new Management can turn it around.
ZFGN NASDAQ was another I refused to write off after a death in a clinical trial, second gen product proven, and nicely rebounding.
- Forums
- ASX - Day Trading
- Day Trading Pre Open - 11 July 2018